Pathology News
admin

About admin@pathologynews.com

This author has not yet filled in any details.
So far admin@pathologynews.com has created 1088 blog entries.

October 2024

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer

2024-10-09T10:04:07+00:00

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part of Owkin’s ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a French consortium to accelerate precision medicine through AI-enabled digital pathology, this tool aims to significantly accelerate and expand access to gBRCA testing that too many patients may not be considered for.

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer2024-10-09T10:04:07+00:00

Deciphex: Launch of IHI JU VICT3R Initiative to Revolutionize Nonclinical Drug and Chemical Safety Evaluation with Virtual Controls

2024-10-07T08:22:20+00:00

Deciphex today announced its participation in VICT3R, a pioneering initiative focused on transforming nonclinical drug and chemical safety evaluation. VICT3R is a public-private partnership supported by the Innovative Health Initiative Joint Undertaking (IHI JU), with the goal of significantly reducing the use of animals in experimental studies. The initiative aims to replace animals in concurrent control groups (CCGs) with Virtual Control Groups (VCGs), leveraging advanced statistical and artificial intelligence (AI) techniques.

Deciphex: Launch of IHI JU VICT3R Initiative to Revolutionize Nonclinical Drug and Chemical Safety Evaluation with Virtual Controls2024-10-07T08:22:20+00:00

PathAI Announces Collaboration with the Crohn’s & Colitis Foundation to Advance Novel IBD Research and Development

2024-10-04T12:23:37+00:00

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced a partnership with the Crohn’s & Colitis Foundation. The collaboration will empower academic and biopharmaceutical researchers to unlock insights into inflammatory bowel disease (IBD) through the unique combination of quantitative histopathology data and well-characterized multi-modal clinical and molecular data.

PathAI Announces Collaboration with the Crohn’s & Colitis Foundation to Advance Novel IBD Research and Development2024-10-04T12:23:37+00:00

Rick Salmon, CEO of PathQA, to Speak at IIC on “A Pathology of Digitisation in Digital Pathology – Scanner Colour QA”

2024-10-04T11:27:02+00:00

Rick Salmon, CEO of PathQA, will be presenting at the International Image Conference (IIC) in London on October 8, 2024, at 9:40 AM. His talk, titled "A Pathology of Digitisation in Digital Pathology - Scanner Colour QA," will delve into the significance of accurate color reproduction in digital pathology and its implications for diagnostics and research.

Rick Salmon, CEO of PathQA, to Speak at IIC on “A Pathology of Digitisation in Digital Pathology – Scanner Colour QA”2024-10-04T11:27:02+00:00

Novel Digital Pathology Tool Uncovers 3D Heterogeneity in PD-L1 Expression in Breast Tumors

2024-10-02T21:23:49+00:00

In a new study, researchers at the National Taiwan University Hospital and JelloX Biotech Inc. developed a novel computer-assisted tool for three-dimensional (3D) imaging of PD-L1 expression in immunofluorescence-stained and optically cleared breast cancer specimens. The proposed 3D framework showed high overall agreement with traditional, clinical-grade two-dimensional (2D) staining techniques in terms of morphological characteristics and PD-L1 expression assessment.

Novel Digital Pathology Tool Uncovers 3D Heterogeneity in PD-L1 Expression in Breast Tumors2024-10-02T21:23:49+00:00

Proscia Launches Concentriq Embeddings and Developer Toolkit to Unleash Pathology AI Development

2024-10-02T16:08:41+00:00

Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, today announced the launch of Concentriq® Embeddings and the Proscia AI Toolkit, enabling life sciences organizations to accelerate the discovery and development of novel therapies and diagnostics. Integrated into Proscia’s Concentriq platform, Concentriq Embeddings seamlessly delivers a collection of pathology foundation models to AI developers and research scientists, allowing them to leverage their organization’s large proprietary datasets and execute models in routine workflows.

Proscia Launches Concentriq Embeddings and Developer Toolkit to Unleash Pathology AI Development2024-10-02T16:08:41+00:00

HistoWiz Expands Histology and Pathology Service Offerings to Include GLP

2024-10-02T08:23:20+00:00

HistoWiz, a leader in digital pathology services, announces the addition of GLP-compliant lab services including routine histology (H&E, trichrome, etc.) and immunohistochemistry (IHC). The addition of GLP leverages HistoWiz’s deep expertise in pre-clinical research pathology processes from wet tissue to slide digitization. Pathology consultation for GLP studies is also available.

HistoWiz Expands Histology and Pathology Service Offerings to Include GLP2024-10-02T08:23:20+00:00

Case Of The Month | October 2024 | Uterine Adenomyosis in a Dog

2024-10-01T09:00:32+00:00

A uterine section showed thickening with cystic cavities and hyperplastic endometrial glands. Microscopically, endometrial glands were found within the myometrium, some lined by keratinized epithelium. The diagnosis is uterine adenomyosis and cystic endometrial hyperplasia.

Case Of The Month | October 2024 | Uterine Adenomyosis in a Dog2024-10-01T09:00:32+00:00

September 2024

Mindpeak Secures $15.3M in Series A Funding to Accelerate Growth in AI-based Digital Pathology

2024-09-30T13:54:31+00:00

Mindpeak, the leader in AI-powered pathological solutions, today announced it has raised $15.3 million in a Series A funding round. The round was led by ZEISS Ventures and InnoVentureFund with participation from - amongst others - AI.FUND and the European Innovation Council Fund. While Mindpeak has a cash-flow positive core business, this new investment will enable the company to further expand the commercialisation of its pioneering technologies across several geographies.

Mindpeak Secures $15.3M in Series A Funding to Accelerate Growth in AI-based Digital Pathology2024-09-30T13:54:31+00:00

Conversation with Meriem Sefta, Owkin

2026-10-06T08:47:25+00:00

In this interview, Meriem Sefta from Owkin discusses her journey from academia to her role at Owkin, where she focuses on applying AI to digital pathology. She explains how Owkin's innovative approach leverages AI to analyze digital pathology slides and link molecular and morphological data for improved diagnostics and drug discovery. Sefta highlights Owkin's partnerships with hospitals to securely access real-world clinical data, which enhances their AI models. She also discusses their CE-marked products for colorectal and breast cancer, as well as the broader impact of AI on the future of pathology, drug development, and personalized medicine.

Conversation with Meriem Sefta, Owkin2026-10-06T08:47:25+00:00
Legal

Bioincyte Ltd is registered in the United Kingdom
under company number 13037659

Get in touch

© Copyright 2025, Bioincyte Ltd

Fields marked with an asterisk (*) are required.
By submitting you agree to our T&C and Privacy Policy

Go to Top